A company born out of ground-breaking research at The University of Warwick has raised almost £3 million of to develop a testosterone patch for people suffering from low libido and reduced zest for life due to the menopause.

Medherant, founded by University of Warwick’s, Professor David Haddleton, is aiming to begin clinical trials of this pioneering treatment in Autumn 2023. Medherant is ultimately aiming to get approval for clinical use, subject to a successful trial.

Assuming trials go well, this would be the only testosterone replacement patch available globally and introduced first in the UK.

Whilst oestrogen and progesterone HRT patches are available, there is currently no transdermal delivery patch available for testosterone delivery for women suffering from adverse symptoms from the menopause. Testosterone is an essential hormone for women and its production declines in post-menopausal people.

David Haddleton, Professor of Chemistry at the University of Warwick and Medherant’s founder said: “This is a very exciting development for us – the potential of this technology to improve women’s lives is huge. The work we’re doing at Medherant and at Warwick isn’t just theoretical, but instead aimed at a problem women are facing which can drastically affect their everyday lives and jobs.”

“This could deliver a product that is much needed and is just not available. With the technology already proven to work we can use our new patch to remove needless misery from women’s daily lives. We hope this will transform life for those suffering from post-menopause issues nationally, and indeed globally”.

Since 2015, Menopause Guidelines issued by National Institute for Health and Care Excellence (NICE) recommend that testosterone supplementation be considered for menopausal people with low sexual desire if hormone replacement therapy alone is not effective.

However, there are no currently approved testosterone products specifically for women. Currently, women seeking treatment for the effects of menopause on libido cannot be prescribed testosterone on the NHS, with many having to use irregular doses of gel only approved for use on men.

This new patch is intended to address this gap in menopause products, providing specific treatment that can be made widely available.

John Burt, CEO of Medherant, said: “Having the funding in place for the first clinical trial of our testosterone patch for post-menopausal people will enable Medherant to take a major step towards registration of the product and being able to address this significant gap in the options available for those in this very important stage of their lives.”

The funding round was led by Mercia Asset Management who focus on businesses in the West Midlands who are looking to expand.

To find out more about the pioneering work of Warwick spin out company Medherant please see here.

To find out more about Professor Haddleton and his work at Warwick please click here and the impact our work is having here.

ENDS

University of Warwick press office contact:

Annie Slinn

Communications Officer | Press & Media Relations | University of WarwickLink opens in a new windowLink opens in a new window 
Email: annie.slinn@warwick.ac.uk

The Polymer Club meeting held on 22 November 2022 at Warwick University was a vibrant meeting with over 100 delegates attending. The latest in polymer science and engineering was on display with talks from industry and academia, and in a poster session where the latest findings towards more sustainable polymer science were discussed. We would like to thank all who attended, their excellent feedback, and we are looking forward to organizing the next event in 2023.

Despite the global movement to tackle plastic pollution, demand for plastics continues to rise. As the world transitions away from fossil fuels, plastics are set to be the biggest driver of oil demand. Single-use plastics – deemed essential in the fight against COVID-19 – have been given a new lease of life. In a world beset with crisis fatigue, what can we do to curb the escalating plastics crisis?

In this book, prof. Alice Mah reveals how petrochemical and plastics corporations have fought relentlessly to protect and expand plastics markets in the face of existential threats to business. From denying the toxic health effects of plastics to co-opting circular economy solutions to plastic waste and exploiting the opportunities offered up by the global pandemic, industry has deflected attention from the key problem: plastics production.

The consequences of unfettered plastics growth are pernicious and highly unequal. We all have a part to play in reducing plastics consumption but we must tackle the problem at its root: the capitalist imperative for limitless growth.